# A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)

> **NCT04600817** · PHASE2 · UNKNOWN · sponsor: **TJ Biopharma Co., Ltd.** · enrollment: 160 (estimated)

## Conditions studied

- Newly Diagnosed Glioblastoma

## Interventions

- **DRUG:** TJ107
- **DRUG:** TJ107 placebo

## Key facts

- **NCT ID:** NCT04600817
- **Lead sponsor:** TJ Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-31
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04600817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04600817, "A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04600817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*